Luke Miels - GlaxoSmithKline PLC President - Global Pharmaceuticals
| GSK Stock | USD 43.50 0.15 0.35% |
President
Mr. Luke Miels is the President Global Pharmaceuticals of the Company. Luke joined GSK and the CET in September 2017 as President, Global Pharmaceuticals, responsible for our commercial portfolio of medicines and vaccines. Previously, he worked for AstraZeneca as Executive Vice President of their European business and, prior to that, was Executive Vice President of Global Product and Portfolio Strategy, Global Medical Affairs and Corporationrationrate Affairs. Before then, he held roles of increasing seniority at Roche and SanofiAventis in the US, Europe and Asia. He is a member of the Board for ViiV Healthcare. Luke holds a BS degree in Biology from Flinders University in Adelaide and an MBA from the Macquarie University, Sydney. since 2021.
| Age | 49 |
| Tenure | 3 years |
| Professional Marks | MBA |
| Address | 980 Great West Road, Brentford, United Kingdom, TW8 9GS |
| Phone | 44 20 8047 5000 |
| Web | https://www.gsk.com |
GlaxoSmithKline PLC Management Efficiency
The company has Return on Asset of 0.1006 % which means that on every $100 spent on assets, it made $0.1006 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.3878 %, implying that it generated $0.3878 on every 100 dollars invested. GlaxoSmithKline PLC's management efficiency ratios could be used to measure how well GlaxoSmithKline PLC manages its routine affairs as well as how well it operates its assets and liabilities. At this time, GlaxoSmithKline PLC's Return On Tangible Assets are quite stable compared to the past year. Return On Assets is expected to rise to 0.15 this year, although the value of Return On Capital Employed will most likely fall to 0.18. Change To Liabilities is expected to rise to about 596.5 M this year, although the value of Total Current Liabilities will most likely fall to about 11.2 B.Similar Executives
| Found 2 records | PRESIDENT Age | ||
| Parker Javid | Lifecore Biomedical | 55 | |
| MD MBA | Shuttle Pharmaceuticals | 55 | |
Management Performance
GlaxoSmithKline PLC ADR Leadership Team
Elected by the shareholders, the GlaxoSmithKline PLC's board of directors comprises two types of representatives: GlaxoSmithKline PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GlaxoSmithKline. The board's role is to monitor GlaxoSmithKline PLC's management team and ensure that shareholders' interests are well served. GlaxoSmithKline PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GlaxoSmithKline PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lynn Elsenhans, Independent Non-Executive Director | ||
| Luke Miels, President - Global Pharmaceuticals | ||
| Hal Barron, Chief Scientific Officer, President - Research & Development, Executive Director | ||
| Harry Dietz, Non-Executive Independent Director, Scientific and Medical Expert | ||
| Emma Walmsley, Chief Executive Officer, Executive Director | ||
| CA BSc, President Development | ||
| Philip Thomson, President Affairs | ||
| Brian McNamara, Chief Executive Officer - GSK Consumer Healthcare | ||
| Charles Bancroft, Non-Executive Independent Director | ||
| Vivienne Cox, Independent Non-Executive Director and Workforce Engagement Director | ||
| Diana Conrad, Senior Vice President - Human Resources | ||
| Roger Connor, President - Global Manufacturing & Supply | ||
| Phil Thomson, Senior Vice President - Global Communications | ||
| Judy Lewent, Non-Executive Independent Director | ||
| Shobie Ramakrishnan, Chief Digital and Technology Officer | ||
| Sarah EltonFarr, Head Relations | ||
| Julie Brown, Chief Officer | ||
| Urs Rohner, Non-Executive Independent Director | ||
| Marvinder Banga, Senior Non-Executive Independent Director | ||
| Anne Beal, Non-Executive Independent Director | ||
| Jesse Goodman, Non-Executive Independent Director and Scientific and Medical Expert | ||
| Laurie Glimcher, Non-Executive Independent Director and Scientific & Medical Expert | ||
| Nick Hirons, Senior Vice President - Global Ethics and Compliance | ||
| Sally Jackson, Senior Vice President - Global Communications and CEO Office | ||
| James Ford, Senior Vice President, Group General Counsel, Legal and Compliance | ||
| Victoria Whyte, Company Secretary | ||
| Tony Wood, Chief Scientific Officer - Designate | ||
| David Redfern, Chief Strategy Officer | ||
| Regis Simard, President - Pharmaceutical Supply Chain | ||
| Jonathan Symonds, Independent Non-Executive Chairman of the Board | ||
| Iain Mackay, Chief Financial Officer, Executive Director | ||
| Karenann Terrell, Chief Digital and Technology Officer | ||
| Deborah Waterhouse, Chief Executive Officer - ViiV Healthcare |
GlaxoSmithKline Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GlaxoSmithKline PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.39 | ||||
| Return On Asset | 0.1 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | 0.38 % | ||||
| Current Valuation | 190.46 B | ||||
| Shares Outstanding | 2.04 B | ||||
| Shares Owned By Institutions | 14.86 % | ||||
| Number Of Shares Shorted | 7.35 M | ||||
| Price To Earning | 11.80 X | ||||
| Price To Book | 4.96 X |
GlaxoSmithKline PLC Investors Sentiment
The influence of GlaxoSmithKline PLC's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in GlaxoSmithKline. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to GlaxoSmithKline PLC's public news can be used to forecast risks associated with an investment in GlaxoSmithKline. The trend in average sentiment can be used to explain how an investor holding GlaxoSmithKline can time the market purely based on public headlines and social activities around GlaxoSmithKline PLC ADR. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
GlaxoSmithKline PLC's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for GlaxoSmithKline PLC's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average GlaxoSmithKline PLC's news discussions. The higher the estimated score, the more favorable is the investor's outlook on GlaxoSmithKline PLC.
GlaxoSmithKline PLC Implied Volatility | 20.17 |
GlaxoSmithKline PLC's implied volatility exposes the market's sentiment of GlaxoSmithKline PLC ADR stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if GlaxoSmithKline PLC's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that GlaxoSmithKline PLC stock will not fluctuate a lot when GlaxoSmithKline PLC's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards GlaxoSmithKline PLC in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, GlaxoSmithKline PLC's short interest history, or implied volatility extrapolated from GlaxoSmithKline PLC options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for GlaxoSmithKline Stock analysis
When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
Is GlaxoSmithKline PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.30) | Dividend Share 0.59 | Earnings Share 2.73 | Revenue Per Share 15.15 | Quarterly Revenue Growth 0.059 |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.